Ireland - English - HPRA (Health Products Regulatory Authority)

stada arzneimittel ag - prucalopride - film-coated tablet - 2 milligram(s) - prucalopride

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - hard capsule - dabigatran etexilate 75 mg - antithrombotic agents

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - hard capsule - dabigatran etexilate 110 mg - antithrombotic agents

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - hard capsule - dabigatran etexilate 150 mg - antithrombotic agents

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - hard capsule - dabigatran etexilate 75 mg - antithrombotic agents

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - hard capsule - dabigatran etexilate 110 mg - antithrombotic agents

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - hard capsule - dabigatran etexilate 150 mg - antithrombotic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - betaine 180 g - powder for oral solution - 1 g - active: betaine 180 g - indicated as an adjunct in the treatment of homocystinuria. indicated to decrease elevated homocysteine blood levels in patients of all age groups with: 1. cystathionine beta-synthase (cbs deficiency) type homocystinuria, or 2. 5,10-methylenetetrahydrofolate reductase deficiency (mthfr deficiency), or 3. cobalamin cofactor metabolism defect (cbl defect) type of homocystinuria. indicated to increase methionine and s-adenosylmethionine blood levels in patients with 5,10-methylenetetrahydrofolate reductase deficiency (mthfr deficiency) and cobalamin cofactor metabolism defect (cbl defect) type of homocystinuria.

United States - English - NLM (National Library of Medicine)

rare disease therapeutics, inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 6 g - cystadane® (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels.  included within the category of homocystinuria are:   - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. pregnancy category c: animal reproduction studies have not been conducted with cystadane.  it is also not known whether cystadane can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  cystadane should be given to a pregnant woman only if clearly needed. it is not known whether cystadane is excreted in human milk.  use only if clearly needed. the majority of case studies of homocystinuria patients treated with cystadane have been pediatric patients, including patients ranging in age from 24 days to 17 years [see clinical studies (14)].   children younger than 3 years of age may benefit

United States - English - NLM (National Library of Medicine)

ropack inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 1 g in 1 g - cystadane ® (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. pregnancy category c: animal reproduction studies have not been conducted with cystadane. it is also not known whether cystadane can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  cystadane should be given to a pregnant woman only if clearly needed. it is not known whether cystadane is excreted in human milk. use only if clearly needed. the majority of case studies of homocystinuria patients treated with cystadane have been pediatric patients, including patients ranging in age from 24 days to 17 years [see clinical studies ( 14)]. children younger than 3 years of age may benefit from dose titration [see dosag